8-K Announcements
6Material company update
May 22, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
Apr 8, 2026·SEC
Ensysce Biosciences, Inc.(ENSC)Earnings, Financials & Key Ratios
ENSC•NASDAQ
Price updated Jun 19, 2026
AboutEnsysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.Show more
- Revenue$5M-2.8%
- EBITDA-$10M-52.1%
- Net Income-$10M-27.4%
- EPS (Diluted)-3.98+12.9%
- EBITDA Margin-202%-56.4%
- Operating Margin-202.12%-56.5%
- Net Margin-200.84%-31.0%
- ROE-0%+100.0%
ENSC Key Insights
Ensysce Biosciences, Inc. (ENSC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ENSC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ENSC Price & Volume
Ensysce Biosciences, Inc. (ENSC) stock price & volume — 10-year historical chart
Loading chart...
ENSC Growth Metrics
Ensysce Biosciences, Inc. (ENSC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years5.21%
3 Years26.16%
TTM-54.6%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-72.91%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM36.79%
Return on Capital
10 Years-99.2%
5 Years-243.39%
3 Years-243.39%
Last Year-0%
ENSC Recent Earnings
Ensysce Biosciences, Inc. (ENSC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.52+28.8%
$0.73
Rev
$960,999-49.4%
$2M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.75+40.5%
$1.26
Rev
$2M+277.8%
$502,966
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$1.29-51.8%
$0.85
Rev
$493,104-29.6%
$700,000
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.79+22.5%
$1.02
Rev
$1M-2.0%
$1M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.52vs $0.73+28.8% | $960,999vs $2M-49.4% |
| Q2 2026 | Mar 30, 2026 | $0.75vs $1.26+40.5% | $2Mvs $502,966+277.8% |
| Q4 2025 | Nov 14, 2025 | $1.29vs $0.85-51.8% | $493,104vs $700,000-29.6% |
| Q3 2025 | Aug 13, 2025 | $0.79vs $1.02+22.5% | $1Mvs $1M-2.0% |
Based on last 12 quarters of dataView full earnings history →
ENSC Peer Comparison
Ensysce Biosciences, Inc. (ENSC) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 PAHC | 1.29B | 31.85 | 26.76 | 27.37% | 6.29% | 30.81% | 2.67 | |
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% |
Compare ENSC vs Peers
Ensysce Biosciences, Inc. (ENSC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ENSC Income Statement
Ensysce Biosciences, Inc. (ENSC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 1.76M | 3.93M | 3.53M | 2.52M | 2.23M | 5.21M | 5.07M | 2.83M |
Revenue Growth % | - | - | - | 122.86% | -10.18% | -28.54% | -11.59% | 133.53% | -2.75% | -54.6% |
Cost of Goods Sold | 0 | 1.56M | 3.4M | 201 | 151 | 19.84M | 7.59M | 7.22M | 0 | 4.88M |
COGS % of Revenue | - | - | 192.88% | 0.01% | 0% | 786.08% | 340.07% | 138.56% | - | - |
Gross Profit | 0▲ 0% | -1.56M▲ 0% | -1.64M▼ 5.1% | 3.93M▲ 339.9% | 3.53M▼ 10.2% | -17.31M▼ 590.3% | -5.36M▲ 69.1% | -2.01M▲ 62.5% | 0▲ 100.0% | -2.06M▲ 0% |
Gross Margin % | - | - | -92.88% | 99.99% | 100% | -686.08% | -240.12% | -38.57% | - | -72.88% |
Gross Profit Growth % | - | - | -5.09% | 339.94% | -10.17% | -590.29% | 69.06% | 62.49% | 100% | - |
Operating Expenses | 146.69K | -600K | 6.93M | 5.54M | 23.4M | 6.91M | 5.36M | 4.72M | 10.24M | 9.78M |
OpEx % of Revenue | - | - | 392.86% | 141.03% | 662.71% | 273.82% | 240.3% | 90.61% | 202.12% | - |
Selling, General & Admin | 146.69K | 0 | 6.93M | 1.15M | 18.71M | 6.91M | 5.36M | 4.72M | 4.93M | 4.71M |
SG&A % of Revenue | - | - | 392.86% | 29.37% | 529.89% | 273.82% | 240.3% | 90.61% | 97.32% | - |
Research & Development | 0 | 0 | 3.4M | 4.39M | 4.69M | 19.84M | 7.59M | 7.22M | 10.38M | 11.84M |
R&D % of Revenue | - | - | 192.88% | 111.66% | 132.82% | 786.08% | 340.07% | 138.56% | 204.81% | - |
Other Operating Expenses | 0 | 0 | -3.4M | 0 | 0 | -19.84M | -7.59M | -7.22M | -5.07M | -3M |
Operating Income | -147K▲ 0% | -959K▼ 552.4% | -8.57M▼ 793.5% | -1.61M▲ 81.2% | -19.87M▼ 1131.7% | -24.22M▼ 21.9% | -10.72M▲ 55.8% | -6.73M▲ 37.2% | -10.24M▼ 52.2% | -11.84M▲ 0% |
Operating Margin % | - | - | -485.74% | -41.04% | -562.71% | -959.91% | -480.41% | -129.17% | -202.12% | -418.88% |
Operating Income Growth % | - | -552.38% | -793.46% | 81.17% | -1131.67% | -21.9% | 55.75% | 37.21% | -52.17% | - |
EBITDA | -27.55K | 2.68M | -8.57M | -1.61M | -19.87M | -24.22M | -10.72M | -6.73M | -10.23M | -6.32M |
EBITDA Margin % | - | - | -485.73% | -41.03% | -562.71% | -959.9% | -480.41% | -129.17% | -202% | -223.84% |
EBITDA Growth % | - | 9811.49% | -420.18% | 81.17% | -1131.82% | -21.9% | 55.75% | 37.21% | -52.07% | -395.61% |
D&A (Non-Cash Add-back) | 0 | 0 | 201 | 201 | 151 | 151 | -3 | 4 | 6.53K | 5.49M |
EBIT | -27.55K | 2.68M | -8.57M | 834.62K | -25.93M | -24.22M | -10.72M | -6.73M | -10.16M | -11.8M |
Net Interest Income | 0 | 0 | 4.25M | -276K | 1.92M | 1.14M | -354K | -1.29M | -18.77K | -18.83K |
Interest Income | 0 | 3.63M | 4.25M | 719.65K | 3.21M | 1.25M | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 995.5K | 1.29M | 109.53K | 353.94K | 1.29M | 18.77K | 18.83K |
Other Income/Expense | 119.14K | 3.63M | -1.53M | 1.45M | -9.28M | 14.41K | 91.91K | -1.26M | 64.76K | 48.64K |
Pretax Income | -27.56K▲ 0% | 2.68M▲ 9810.4% | -10.1M▼ 477.5% | -160.88K▲ 98.4% | -29.15M▼ 18017.1% | -24.21M▲ 16.9% | -10.63M▲ 56.1% | -7.99M▲ 24.8% | -10.18M▼ 27.4% | -11.79M▲ 0% |
Pretax Margin % | - | - | -572.7% | -4.09% | -825.38% | -959.33% | -476.29% | -153.3% | -200.85% | -417.16% |
Income Tax | 3.63K | 553.92K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -13.19% | 20.7% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -31.19K▲ 0% | -1.34M▼ 4205.5% | -10.1M▼ 652.2% | 56.77K▲ 100.6% | -29.08M▼ 51330.8% | -24.17M▲ 16.9% | -10.61M▲ 56.1% | -7.99M▲ 24.7% | -10.18M▼ 27.4% | -11.79M▲ 0% |
Net Margin % | - | - | -572.7% | 1.44% | -823.62% | -957.93% | -475.71% | -153.3% | -200.84% | -417.14% |
Net Income Growth % | - | -4205.45% | -652.22% | 100.56% | -51330.78% | 16.89% | 56.09% | 24.74% | -27.4% | -72.91% |
Net Income (Continuing) | -31.19K | 2.12M | -10.1M | -160.88K | -29.15M | -24.21M | -10.63M | -7.99M | -10.18M | -11.79M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | -217.63K | -279.81K | -315.21K | -328.41K | -328.48K | -328.97B | -328.97K |
EPS (Diluted) | -0.01▲ 0% | -0.22▼ 4130.8% | 0.24▲ 209.1% | 0.56▲ 133.3% | -355.68▼ 63614.3% | -139.44▲ 60.8% | -4.69▲ 96.6% | -4.57▲ 2.6% | -3.98▲ 12.9% | -1.72▲ 0% |
EPS Growth % | - | - | 209.09% | 133.33% | -63614.29% | 60.8% | 96.64% | 2.56% | 12.91% | 36.79% |
EPS (Basic) | -0.01 | -0.22 | 0.24 | 0.56 | -355.68 | -139.44 | -4.69 | -4.57 | -3.98 | - |
Diluted Shares Outstanding | 5.98M | 6.01M | 6.09M | 6.37M | 84.02K | 179.93K | 2.26M | 1.75M | 25.57M | 6.84M |
Basic Shares Outstanding | 5.98M | 6.01M | 6.09M | 4.46M | 84.02K | 179.93K | 2.26M | 1.75M | 2.56M | 6.84M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ENSC Balance Sheet
Ensysce Biosciences, Inc. (ENSC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.31M | 1.92M | 618.59K | 347.88K | 15.66M | 5.3M | 2.29M | 5.34M | 7.24T | 2.01M |
Cash & Short-Term Investments | 2.09M | 1.66M | 341.54K | 194.21K | 12.26M | 3.15M | 1.12M | 3.5M | 3.5M | 745.48K |
Cash Only | 2.09M | 1.66M | 341.54K | 194.21K | 12.26M | 3.15M | 1.12M | 3.5M | 3.5M | 745.48K |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 170.53K | 173.55K | 0 | 441.72K | 276.82K | 97.56K | 124.11K | 420.35K | 0 |
Days Sales Outstanding | - | - | 35.91 | - | 45.66 | 40.04 | 15.96 | 8.7 | 30.28 | 52.63 |
Inventory | 0 | 0 | 0 | 0 | -441.72K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 68.81K | 23.54K | 2.59M | 1.33M | 18K | 18K | 2.93T | 1.26M |
Total Non-Current Assets | 200.12M | 202.92M | 5.35K | 3.93K | 754.76K | 585.88K | 419.22K | 252.55K | 210.01B | 159.26K |
Property, Plant & Equipment | 0 | 0 | 351 | 151 | 24.72B | 0 | 0 | 0 | 124.13B | 117.6K |
Fixed Asset Turnover | - | - | 5025.53x | 26034.50x | 0.00x | - | - | - | 0.00x | 25.05x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 200.12M | 202.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 5K | 3.78K | -24.72B | 585.88K | 419.22K | 252.55K | 85.88B | 41.67K |
Total Assets | 202.43M▲ 0% | 204.83M▲ 1.2% | 623.94K▼ 99.7% | 351.81K▼ 43.6% | 16.42M▲ 4566.6% | 5.89M▼ 64.2% | 2.71M▼ 54.0% | 5.6M▲ 106.7% | 7.45T▲ 133145694.2% | 2.17M▲ 0% |
Asset Turnover | - | - | 2.83x | 11.17x | 0.22x | 0.43x | 0.82x | 0.93x | 0.00x | 0.62x |
Asset Growth % | - | 1.19% | -99.7% | -43.62% | 4566.58% | -64.15% | -53.98% | 106.69% | 99999900% | 13.43% |
Total Current Liabilities | 156.24K | 437.89K | 7.3M | 7.01M | 16.48M | 9.46M | 3.33M | 2.21M | 4.57T | 2.84M |
Accounts Payable | 0 | 0 | 540.78K | 1.72M | 301.1K | 2.94M | 1.94M | 1.36M | 3.27M | 1.61M |
Days Payables Outstanding | - | - | 58.01 | 1000K | 727.83K | 54.17 | 93.14 | 68.62 | - | 119.26 |
Short-Term Debt | 0 | 0 | 2.62M | 4.25M | 12.75M | 4.27M | 854.7K | 301.66K | 306.71B | 245.85K |
Deferred Revenue (Current) | 0 | 0 | 0 | 159.05K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 152.6K | 437.89K | 2.93M | 670.26K | 0 | 0 | 0 | 0 | 4.26T | 980.78K |
Current Ratio | 14.77x | 4.38x | 0.08x | 0.05x | 0.95x | 0.56x | 0.69x | 2.42x | 1.59x | 0.71x |
Quick Ratio | 14.77x | 4.38x | 0.08x | 0.05x | 0.98x | 0.56x | 0.69x | 2.42x | 1.59x | 0.71x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -66.63 |
Total Non-Current Liabilities | 7M | 7M | 0 | 6.75M | 8.09M | 450.49K | 26.39K | 10.1K | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 4.44M | 140.15K | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 1.76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 3.65M | 310.35K | 26.39K | 10.1K | 0 | 0 |
Total Liabilities | 7.16M | 7.44M | 7.3M | 7.01M | 24.58M | 9.91M | 3.36M | 2.22M | 4.57T | 2.84M |
Total Debt | 0 | 0 | 2.62M | 4.27M | 17.21M | 4.43M | 854.7K | 301.66K | 301.66K | 245.85K |
Net Debt | -2.09M | -1.66M | 2.28M | 4.08M | 4.95M | 1.29M | -268.91K | -3.2M | -3.2M | -499.63K |
Debt / Equity | - | - | - | - | - | - | - | 0.09x | 0.00x | -0.37x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | -0.62x | - | - | - | - | - | - | - | 0.08x |
Interest Coverage | - | - | - | 0.84x | -20.02x | -221.16x | -30.28x | -5.22x | -541.24x | -626.43x |
Total Equity | 195.27M▲ 0% | 197.39M▲ 1.1% | -6.68M▼ 103.4% | -6.66M▲ 0.3% | -8.16M▼ 22.5% | -4.03M▲ 50.6% | -651.27K▲ 83.8% | 3.38M▲ 619.0% | 2.88T▲ 85349073.5% | -669.01K▲ 0% |
Equity Growth % | - | 1.09% | -103.38% | 0.27% | -22.52% | 50.61% | 83.84% | 618.98% | 85349073.46% | -119.08% |
Book Value per Share | 32.63 | 32.87 | -1.10 | -1.05 | -97.10 | -22.40 | -0.29 | 1.93 | 112800.11 | -0.10 |
Total Shareholders' Equity | 195.27M | 197.39M | -6.68M | -6.44M | -7.88M | -3.71M | -322.86K | 3.71M | 3.21T | -340.04K |
Common Stock | 673 | 604 | 5.99K | 1.58K | 124 | 53 | 315 | 136 | 459M | 929 |
Retained Earnings | -31.19K | 2.09M | -56.02M | -55.96M | -85.85M | -110.93M | -121.56M | -129.54M | -139.72T | -143.28M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -673 | -604 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | -217.63K | -279.81K | -315.21K | -328.41K | -328.48K | -328.97B | -328.97K |
ENSC Cash Flow Statement
Ensysce Biosciences, Inc. (ENSC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -251.83K | -1.24M | 10.99M | -1.25M | -8.24M | -17.89M | -10.78M | -7.5T | -7.81T | -9.6M |
Operating CF Margin % | - | - | 623.31% | -31.73% | -233.41% | -708.87% | -483.19% | -99999900% | -99999900% | - |
Operating CF Growth % | - | -391.7% | 987.93% | -111.34% | -560.78% | -117.02% | 39.73% | -69598346.45% | -4.05% | -304.82% |
Net Income | -31.19K | -1.34M | 365.95K | -160.88K | -29.15M | -24.21M | -10.63M | -7.99M | -10.18T | -11.79M |
Depreciation & Amortization | 0 | 0 | 0 | 201 | 151 | 0 | 0 | 0 | 6.53B | 6.53K |
Stock-Based Compensation | 0 | 0 | 0 | 178.68K | 121.76K | 1.07M | 879.16K | 110.72B | 668.68B | 511.35K |
Deferred Taxes | 0 | 1.76K | -1.76K | -2.45M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -231.1K | -317.21K | 8.17M | 997.46K | 22.09M | -233.42K | -85.79K | -7.61T | 1.69T | 2.58M |
Working Capital Changes | -101.5K | 273.13K | 2.46M | 185.1K | -1.3M | 5.48M | -947.08K | -851.25K | 1.52M | 1.95M |
Change in Receivables | 0 | -170.53K | 0 | 173.55K | -441.72K | 164.9K | 179.26K | -26.55K | -296.23K | 22K |
Change in Inventory | 0 | 0 | 0 | -173.55K | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 111.96K | 317.28K | 0 | 1.18M | -1.42M | 2.64M | -1.23M | -578.93K | 1.82M | 1.47M |
Cash from Investing | -200M | 838.59K | -566.29K | 183.4M | 0 | 4.5K | 0 | 0 | -123.64B | -123.64K |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -123.64K | -123.64K |
CapEx % of Revenue | - | - | 0% | - | - | - | - | - | 2.44% | 4.38% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 838.59K | 0 | 183.4M | 0 | 4.5K | 0 | 0 | -123.64B | 0 |
Cash from Financing | 202.34M | -32K | -11.03M | 1.1M | 20.31M | 8.77M | 8.76M | 9.88T | 8.74T | 7.42M |
Debt Issued (Net) | 0 | 0 | 566.27K | 1.1M | 13.91M | 6.13M | 605.43K | -485.19K | 0 | -64.05K |
Equity Issued (Net) | 202.34M | -32K | -11.59M | 0 | 6.63M | 3.78M | 9.05M | 1.67M | 9.85M | 6.9M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -290M | 0 | 0 |
Share Repurchases | 0 | 0 | -11.58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | -225.68K | -1.14M | -899.55K | 9.88T | 8.74T | 578.25K |
Net Change in Cash | 2.09M▲ 0% | -431.68K▼ 120.7% | -597.25K▼ 38.4% | -147.32K▲ 75.3% | 12.07M▲ 8293.3% | -9.12M▼ 175.5% | -2.02M▲ 77.8% | 2.38T▲ 117507898.5% | 808.28B▼ 66.0% | -2.31M▲ 0% |
Free Cash Flow | -251.83K▲ 0% | -1.24M▼ 391.7% | 10.99M▲ 987.9% | -1.25M▼ 111.3% | -8.24M▼ 560.8% | -17.89M▼ 117.0% | -10.78M▲ 39.7% | -7.5T▼ 69598346.5% | -7.81T▼ 4.0% | -9.72M▲ 0% |
FCF Margin % | - | - | 623.31% | -31.73% | -233.41% | -708.87% | -483.19% | -99999900% | -99999900% | -344.13% |
FCF Growth % | - | -391.7% | 987.93% | -111.34% | -560.78% | -117.02% | 39.73% | -69598346.45% | -4.05% | -67.6% |
FCF per Share | -0.04 | -0.21 | 1.81 | -0.20 | -98.10 | -99.41 | -4.76 | -999999.00 | -305243.29 | -1.42 |
FCF Conversion (FCF/Net Income) | 8.07x | 0.92x | -1.09x | -21.97x | 0.28x | 0.74x | 1.02x | 939363.97x | 767150.37x | 0.82x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 1.6K | 1.6K | 1.6K | 3.2K | 3.2K | 2.5K | 0 |
ENSC Key Ratios
Ensysce Biosciences, Inc. (ENSC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -0.68% | -10.59% | - | - | - | - | -585.41% | -0% | -766.5% |
Return on Invested Capital (ROIC) | -0.37% | -6.72% | - | - | - | - | - | -0% | 0% |
Gross Margin | - | -92.88% | 99.99% | 100% | -686.08% | -240.12% | -38.57% | - | -72.88% |
Net Margin | - | -572.7% | 1.44% | -823.62% | -957.93% | -475.71% | -153.3% | -200.84% | -417.14% |
Debt / Equity | - | - | - | - | - | - | 0.09x | 0.00x | -0.37x |
Interest Coverage | - | - | 0.84x | -20.02x | -221.16x | -30.28x | -5.22x | -541.24x | -626.43x |
FCF Conversion | 0.92x | -1.09x | -21.97x | 0.28x | 0.74x | 1.02x | 939363.97x | 767150.37x | 0.82x |
Revenue Growth | - | - | 122.86% | -10.18% | -28.54% | -11.59% | 133.53% | -2.75% | -54.6% |
Related:ENSC Dividend History·ENSC Revenue History·ENSC Price History·ENSC P/E History·ENSC Financial Ratios·ENSC Institutional Holders
ENSC SEC Filings & Documents
Ensysce Biosciences, Inc. (ENSC) SEC filings — annual & quarterly reports (10-K, 10-Q)
ENSC Frequently Asked Questions
Ensysce Biosciences, Inc. (ENSC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ensysce Biosciences, Inc. (ENSC) reported $2.8M in revenue for fiscal year 2025.
Ensysce Biosciences, Inc. (ENSC) saw revenue decline by 2.8% over the past year.
Ensysce Biosciences, Inc. (ENSC) reported a net loss of $11.8M for fiscal year 2025.
Dividend & Returns
Ensysce Biosciences, Inc. (ENSC) has a return on equity (ROE) of -0.0%. Negative ROE indicates the company is unprofitable.
Ensysce Biosciences, Inc. (ENSC) had negative free cash flow of $9.7M in fiscal year 2025, likely due to heavy capital investments.